Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2006 | 06-2005 | 09-2004 | 09-2003 | 09-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,218 | -4,269 | 76 | -60 | -59 |
| Depreciation Amortization | 660 | 223 | N/A | N/A | N/A |
| Accounts receivable | -547 | -50 | N/A | N/A | N/A |
| Other Working Capital | -290 | 483 | -9 | N/A | 42 |
| Other Operating Activity | 1,392 | 228 | -77 | 41 | 9 |
| Operating Cash Flow | $-7,003 | $-3,386 | $-10 | $-19 | $-9 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -475 | -724 | N/A | N/A | N/A |
| Net Acquisitions | 33 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -395 | -432 | 0 | 0 | 0 |
| Investing Cash Flow | $-837 | $-1,156 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,197 | 3,903 | N/A | N/A | N/A |
| Debt Repayment | -125 | -3 | N/A | N/A | N/A |
| Common Stock Issued | 7,910 | 1,848 | N/A | N/A | N/A |
| Common Stock Repurchased | -1 | 0 | N/A | N/A | N/A |
| Other Financing Activity | -586 | -24 | 10 | 19 | 9 |
| Financing Cash Flow | $8,395 | $5,724 | $10 | $19 | $9 |
| Beginning Cash Position | 1,653 | 470 | N/A | N/A | N/A |
| End Cash Position | 2,208 | 1,653 | N/A | N/A | N/A |
| Net Cash Flow | $554 | $1,183 | $N/A | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,003 | -3,386 | -10 | -19 | -9 |
| Capital Expenditure | -475 | -724 | N/A | N/A | N/A |
| Free Cash Flow | -7,478 | -4,110 | -10 | -19 | -9 |